- $9.63bn
- $9.82bn
- $1.22bn
- 91
- 18
- 68
- 62
Annual income statement for BIO-TECHNE, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 931 | 1,106 | 1,137 | 1,159 | 1,220 |
| Cost of Revenue | |||||
| Gross Profit | 634 | 758 | 770 | 773 | 811 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 694 | 809 | 789 | 952 | 1,117 |
| Operating Profit | 237 | 297 | 348 | 207 | 102 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 148 | 301 | 339 | 186 | 98.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 140 | 263 | 285 | 168 | 73.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 140 | 272 | 285 | 168 | 73.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 140 | 272 | 285 | 168 | 73.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.918 | 1.67 | 1.48 | 1.3 | 1.23 |
| Dividends per Share |